Additionally, we suggest that SLC1A5 is a potential therapeutic target for overcoming endocrine resistance and demonstrates the prognostic value of both SLC1A5 and TALDO1 as biomarkers for predicting endocrine therapy guide in luminal breast cancer. The gene discussed is TALDO1; the disease is breast cancer.